MAIA Biotechnology, Inc. (MAIA)
USD 1.94
(-11.82%)
USD 1.94
(-11.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.18 Million USD | -27.25% |
| 2022 | -16.17 Million USD | -104.89% |
| 2021 | - USD | -10.98% |
| 2020 | - USD | -0.77% |
| 2019 | 242.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.83 Million USD | -124.26% |
| 2024 Q1 | -3.96 Million USD | 36.59% |
| 2023 Q1 | -4.13 Million USD | 20.68% |
| 2023 FY | - USD | -28.36% |
| 2023 Q3 | -4.89 Million USD | -5.82% |
| 2023 Q4 | -6.4 Million USD | -30.88% |
| 2023 Q2 | -4.62 Million USD | -11.91% |
| 2022 Q2 | -3.3 Million USD | 3.17% |
| 2022 Q1 | -3.41 Million USD | -15.52% |
| 2022 FY | - USD | -104.89% |
| 2022 Q4 | -5.21 Million USD | -32.55% |
| 2022 Q3 | -3.93 Million USD | -18.91% |
| 2021 Q2 | -1.5 Million USD | -43.03% |
| 2021 FY | - USD | -10.98% |
| 2021 Q1 | -1.05 Million USD | -1865.19% |
| 2021 Q4 | -2.95 Million USD | -32.37% |
| 2021 Q3 | -2.23 Million USD | -48.58% |
| 2020 Q4 | 59.51 Thousand USD | 107.25% |
| 2020 Q3 | -820.53 Thousand USD | 0.0% |
| 2020 FY | - USD | -0.77% |
| 2019 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 36.289% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 49.44% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 60.527% |
| Azitra, Inc. | -10.67 Million USD | -89.094% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | -146.728% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -194.106% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 29.432% |
| CEL-SCI Corporation | -27.56 Million USD | 26.771% |
| iBio, Inc. | -14.02 Million USD | -43.944% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 18.399% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 11.578% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | -45.458% |
| NovaBay Pharmaceuticals, Inc. | -4.8 Million USD | -320.466% |
| NanoViricides, Inc. | -7.75 Million USD | -160.18% |
| Oragenics, Inc. | -20.87 Million USD | 3.33% |
| BiomX Inc. | -22.81 Million USD | 11.539% |
| BiomX Inc. | -22.81 Million USD | 11.539% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 273.224% |
| Palatin Technologies, Inc. | -29.03 Million USD | 30.48% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 42.472% |